Wayne State University
Wayne State University Dissertations

1-1-2014

The Tumor-Suppressive Role Of Secreted Maspin
Via The Exosomes
Ivory Dean
Wayne State University,

Follow this and additional works at: http://digitalcommons.wayne.edu/oa_dissertations
Part of the Biology Commons
Recommended Citation
Dean, Ivory, "The Tumor-Suppressive Role Of Secreted Maspin Via The Exosomes" (2014). Wayne State University Dissertations. Paper
1089.

This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in
Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState.

A TUMOR-SUPPRESSIVE ROLE OF MASPIN SECRETED VIA THE EXOSOMES
by
IVORY DEAN
DISSERTATION
Submitted to the Graduate School
of Wayne State University,
Detroit, Michigan
in partial fulfillment of the requirements
for the degree of

DOCTOR OF PHILOSOPHY
2014
MAJOR: CANCER BIOLOGY
Approved by:

Advisor

Date

© Copyright by
Ivory Dean
2014
All Rights Reserved

DEDICATION
This dissertation is specifically dedicated to my nephew, Jarrius, and my little
brother, Nicholas. I hope I have been a positive example for you. I hope this inspires
you to grow up to be positive, respectable, educated, successful men. Jarrius, you have
a great spirit and kind heart. I love listening to you speak passionately about what you
want to do when you grow up. I hope you achieve your goals. Do not let anyone stop
you. As your mother has told you many times, you are my mini-me, which gives me
confidence that you will fare well in this big and crazy world. Nicholas, I am so happy to
have you be a part of my life. You are the definition of a fighter. From the moment you
were born, you were determined to survive. I fell instantly in love with you the moment I
saw you.
This dissertation is dedicated to Lori Hensley, whose kindness is immeasurable.
You have been my biggest supporter for many years. Thank you for always being so
kind and generous. As I have grown and matured, experienced trials and tribulations,
and achieved personal and professional triumphs, you have been a true friend. I will
forever treasure our friendship.
Finally, I would like to dedicate this dissertation to my mother, Robin, and my
sister, Ebony. Robin, you have taught me to think “in spite of” whenever I encounter
hardships. Through your life lessons, I have learned to succeed “in spite of”. You taught
me to never give up and that bad times are only temporary. You built my confidence. I
am who I am “in spite of”. Ebony, you are my polar opposite in namesake and in life.
You are also my built-in best friend. I would not be who I am without you. I would have
let the world pass me by with my nose buried in books if you had not made look up.

ii

ACKNOWLEDGMENTS
First and foremost, I would like to thank my mentor Dr. Shijie Sheng. Thank you
for your guidance and trust. Thank you for giving me the freedom to pursue my research
as it kept changing over and over again. I am also grateful for your many stories about
your life. I will treasure them because they gave me a new perspective of the world.
Also, I would like to thank my committee members, Drs. Stanley Terlecky, Rafael
Fridman, Raymond Mattingly and Hyeong-Reh Kim, for their valuable expertise. To Dr.
Larry Matherly, thank you for always believing in me and pushing me to be a great
scientist. To Dr. Robert Pauley, thank you for seeing my potential, accepting me into the
Cancer Biology program and supporting me. I would also like to thank Drs. Joseph
Dunbar and Rasheeda Zafar for providing me with so many opportunities to gain
experience and knowledge as a scientist and professional. I would like to thank the past
and current Sheng laboratory members. A special thanks to Drs. Margarida Bernardo
and Sijana Dzinic for being selfless and great teachers. You always took time out of
your busy schedules to train me and answer my questions without acting as if it was a
burden. Finally, to my colleagues and friends, Brittany Haynes, Richard Warner, Alyssa
Bottrell, and Abdo Najy, thanks for being listening ears, whether the topic was scientific
or non-scientific. I have enjoyed your company, advice and friendships. Science,
research and learning are as much as a community effort as it is an individual one.
Thank you all for collectively assisting in my scientific training.

iii

PREFACE
This work was supported by the Dean’s Diversity Fellowship from 2008 - 2009,
NIH R25GM058905 Initiative for Maximizing Diversity Grant from 2009-2010, Ruth L.
Kirschstein National Research Service Award T32-CA009531 from 2010 - 2011,
Rumble Fellowship from 2011- 2012, Ruth L. Kirschstein National Research Service
Award 1F31CA171788-01 from 2012 - 2014. This work was also supported by the
NIH/NCI RO1-CA127735, NIH/NCI RO1-CA084176 and the Ruth Sager Memorial fund,
which were acquired through the diligence of Shijie Sheng, Ph.D.

iv

TABLE OF CONTENTS
Dedication………………..……………..………………………………………………………ii
Acknowledgments…………………..…...…………………………………………………….iii
Preface………….……………………………………………………………………………….iv
List of Tables…………………………………...……………………………………………….vi
List of Figures……………….………………………..………………………………………..vii
Chapter 1 – Introduction………..……………………….……………………………………1
Chapter 2 – Materials and Method…………..………………………………………...……16
Chapter 3 – Results………….………………………………………………………………..28
Chapter 3A: Investigating the Differential Regulation of Exosomal Maspin in NonMalignant Cells and Tumor Cells…………………………………………………….28
Chapter 3B: The Biological Function of Exosomal Maspin in Paracrine
Communication in the Microenvironment…………………………………………..45
Chapter 4 – Discussion..…………..………………………………………………………….52
References...…………………………………..….……………………………………………62
Abstract…...…………...……………………………………………………………………….74
Autobiographical Statement…….……..…………………………………………..…………76

v

LIST OF TABLES
Table 1: Average Size Distribution of the Exosomes...……………………………………32
Table 2: Average Zeta potential of the Exosomes...……………………………………….35
Table 3: Prediction for Non-Classical Secretion of Maspin....…………………………....36
Table 4: Inhibitors of Secretion………………………………....…………………………....46

vi

LIST OF FIGURES
Figure 1: The physical characteristics of the exosomes by AFM………………………..31
Figure 2: Size distribution of exosomes measured by DLS……………………………….32
Figure 3: Electron microscopy of the exosomes……………………………………………34
Figure 4: Cytoplasmic ribosomes translate maspin mRNA……………………………….37
Figure 5: Maspin is not secreted through the ER-Golgi secretory pathway……………..38
Figure 6: Co-localization of maspin with the endo-lysosomal protein, LAMP-2………...39
Figure 7: Exosomal maspin is secreted by non-malignant cells………………………….41
Figure 8: Loss of maspin expression results in absence of exosomal maspin…………42
Figure 9: Maspin re-expression does not induce exosomal maspin secretion………….44
Figure 10: Exosomal maspin and soluble maspin are secreted independently………...46
Figure 11: Maspin is not at the membrane surface of the exosome……………………..48
Figure 12: Knockdown of intracellular maspin affects maspin secretion………………..50
Figure 13: Cell viability of the NIH 3T3 cells after exosome treatment.………………….51
Figure 14: Exosome uptake by NIH 3T3 fibroblasts……………………………………….52
Figure 15: Loss of exosomal maspin results in increased motility for NIH 3T3 cells…..53
Figure 16: Messenger RNA levels of various genes in the NIH 3T3 cells………………55
Figure 17: Hypothetical Model of Secreted Soluble and Exosomal Maspin Activity……56

vii

1
CHAPTER 1: Introduction and Hypothesis
Cancer Statistics
Prostate and breast cancers are the most commonly diagnosed cancers among
men and women in the United States, respectively, and are ranked second for the
highest death rates.1 Lung cancer is the second most commonly diagnosed cancer but
has the highest death rate compared to all other cancers.1 When broadened globally,
breast cancer is remains the most commonly diagnosed cancer in women, but
increases in rank as the leading cause of cancer deaths.2 This trend is mimicked in both
developed and developing countries. Worldwide, prostate cancer falls to the second
most commonly diagnosed cancer among men and is the sixth cause of cancer deaths.2
Prostate cancer incidence further drops to the sixth most commonly diagnosed in
developing countries, and it remains the sixth cause of cancer death. In contrast,
prostate cancer is the most commonly diagnosed cancer in developed countries but is
the third cause of cancer deaths among men. Globally, lung cancer remains the leading
cause of cancer deaths in men but is the second leading cause of cancer deaths among
women.2 In incidence, lung cancer is the most commonly diagnosed in developing
countries and is the second most commonly diagnosed in developed countries among
men. For women, lung cancer ranks third in diagnosis for both developed and
developing countries. Of note, these statistics exclude basal and squamous cell skin
cancers.
Clinicians evaluate cancers using the TNM (tumor, node, and metastasis) staging
system established by The American Joint Committee on Cancer (AJCC). Under the
TNM system, the degree of local invasion is assessed in the primary tumor (T), the
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presence or absence of local metastasis is assessed in the lymph nodes (N), and the
presence or absence of distant metastasis is evaluated in the organs (M).3 The
combination of T, N and M is used to assign the tumor a stage (0 – 4). In prostate
cancer, clinicians also use the Gleason grading system to establish a tumor grade to
determine the aggressiveness of the tumor.4 The Gleason grade is determined from the
histology of prostate cancer tissue samples. The prognostic value of stage and grade
are helpful, but has its limitations.

The Tumor Microenvironment: An Unhealable Wound
Cancer is a general term for a heterogeneous disease, in which the malignancy
predominantly stems from metastasis.5 Metastasis is characterized by the migration of
aggressive tumor cells from one organ to another. In the continuum of metastasis, the
vascular and lymph networks provide the means for tumor cells to escape their original
microenvironment and colonize distant organs. Interestingly, metastasis does not seem
to be a random process. Metastatic tumors undergo organ-specific metastasis, creating
a pattern for metastasis.6,7 For example, negative breast cancer cells often metastasize
to the liver, bone, and brain.
Aggressive tumor cells often infiltrate nearby areas by disrupting the homeostasis
of the microenvironment through the degradation of the extracellular matrix (ECM).8,9
Extracellular matrix homeostasis is tightly maintained in the normal microenvironment
during development and other physiological or non-malignant pathological processes.
During wound healing in the normal microenvironment, platelets aggregate to form a
plug and a fibrin clot is formed. Macrophages infiltrate the local area and secrete growth
factors, which activate stromal cells such as fibroblasts. Fibroblasts secrete matrix

3
metalloproteases (MMPs), which degrade the ECM, and differentiate into myofibroblasts
to facilitate wound contraction. Vascular endothelial cells are stimulated to undergo
angiogenesis. Finally, epithelial cells increase cell motility in order to reform tissue. In
contrast, homeostasis is disrupted in the tumor microenvironment with increased
degradation of the ECM. Continuous degradation of the ECM promotes tumor invasion
and metastasis. This phenomenon is analogous to an unhealable wound.10 Similar to
wound healing, tumor cells secrete growth factors that activate the stromal cells in the
tumor microenvironment. Fibroblasts differentiate into myofibroblasts and vascular
endothelial cells are induced to undergo angiogenesis. Tumor-associated reactive
stromal cells are induced to constitutively secrete pro-collagen. Fibroblasts and
macrophages secrete proteases, such as MMPs, which degrade the ECM. Excessive
production of proteases at the invasive front prevents the collagen deposit from
mounting to a physical barrier and forming scar tissue.9,10 The imbalance between ECM
deposition and ECM degradation gives the tumor microenvironment the characteristics
of an unhealable wound.

Maspin: A Serine Protease Inhibitor
The discovery of maspin, through subtractive hybridization in nonmalignant and
malignant breast cell lines, initiated the research of maspin as a tumor suppressor.11
Maspin, a 42 kDa protein, is a clade B member of the serine protease inhibitor (serpin)
superfamily. Hence, maspin (mammary serine protease inhibitor) is alternatively named
SERPINB5. Maspin maps to chromosome 18q21.3 and shares high sequence
homology with other serpins, such as equine neutrophil-monocyte elastase inhibitor
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(43%), human neutrophil-monocyte elastase inhibitor (39%), human squamous cell
carcinoma antigen (34%), human plasminogen activator inhibitor 2 (PAI-2; 31%), and
chicken ovalbumin (31%).11
The tertiary structure of maspin consists of three anti-parallel β-pleated sheets
and nine α-helices.12 The reactive site loop (RSL), a common serpin structural feature,
is located between the A and C β-pleated sheets. The RSL of maspin contains an
arginine residue at its p1 site, suggesting it is an arginine-specific protease inhibitor.13
However, maspin’s RSL does not undergo the stressed to relaxed transition, which is
important for classic serpin inhibition. Unlike classical inhibitory serpins, the RSL of
maspin does not have a conserved hinge region.11 Typically, the RSL of an inhibitory
serpin is cleaved and inserted into the center of the β-pleated sheet after the serpin has
docked to its target, which creates an additional β-strand. Although maspin’s RSL does
not act like an inhibitory serpin, the RSL is necessary for maspin’s tumor suppressive
activity.11,13 Immediately preceding the putative p1p1´ site of maspin is a KDEL (lysineaspartate-glutamate-leucine) sequence, which seems to be necessary in determining
the subcellular localization and tumor suppressive function of maspin.14 Out of the nine
helices, the G-helix of maspin is able to undergo a novel and unprecedented
conformational change, in which the G-helix switches between an open and a closed
conformation.12 Ravenhill et al (2010) showed that maspin modulates cell adhesion and
migration via its G-helix.15
Maspin’s expression is regulated by methylation for epithelial-specific expression
in normal tissues. In non-epithelial tissues, the maspin gene is silenced through
methylation.16 Of note, maspin expression has been detected in vitro in human umbilical
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vein endothelial cells (HUVEC) and prostate smooth muscle cells.17,18 Therefore,
maspin expression in non-epithelial cells may be due to in vitro cell culture conditions.

The Tumor-Suppressive Role of Maspin
Maspin is a class II (epigenetically-silenced) tumor suppressor gene. Clinical
samples of normal epithelium tissues show that maspin is mainly expressed in the
nucleus.11 Maspin knockout was demonstrated to be embryonically lethal in an in vivo
mouse model.19 However, a recently published study reported viable embryos from
maspin conditional knockout mouse models.20 Teoh et al (2014) asserted that the neo
selection cassette that was left in the maspin gene of the maspin knockdown mouse
model of Gao et al (2004) may have resulted in the embryonic lethality. Furthermore,
Teoh et al (2014) asserted that their data supports their hypothesis that maspin is not a
tumor suppressor since they could not reproduce the results previously published by
others. Recent evidence in the Sheng Laboratory may confirm that maspin is not
embryonically lethal (unpublished observation). The Sheng laboratory will continue to
investigate the embryonic lethality of maspin. Additionally, there is a wide array of data
in the literature that supports the notion that maspin is a tumor suppressor. The Sheng
laboratory and others have independently verified that maspin acts as a tumor
suppressor.
In tumor cells, maspin was shown to be epigenetically silenced by aberrant
(hyper)-methylation.21,22 At the transcriptional level, maspin expression was shown to be
positively regulated by the Ets element, which is active in normal epithelial cells, but
inactive in tumor cells, of both breast and prostate.23,24 In normal mammary epithelial
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cells, the AP-1 element cooperates with the Ets to positively regulate maspin
expression.23 In normal prostate and prostate cancer cells, maspin expression was
negatively regulated by the hormone response element (HRE), which was targeted by
the androgen receptor but no other steroid receptor.24 Of note, androgen ablation was
shown to induce maspin promoter activity in prostate cancer cells.25 The transcription
factor, E2F1, was shown to mediate the up-regulation of the maspin gene in
osteosarcoma cells.26 Furthermore, re-expression of wild-type p53 was shown to
activate maspin expression by binding directly to the p53 consensus-binding site
present in the maspin promoter in both breast and prostate cancer cells.27,28
The loss of maspin has been associated with increased malignancy, with a less
differentiated phenotype, and with increased angiogenesis.

11,25,29-31

Re-expression of

maspin in breast and prostate cancer cells has been shown to push the cancer cells
toward a more epithelial-like state in vitro and in vivo.32-35 The better-differentiated
phenotype

was

concurrent

with

decreased

tumorigenicity,

organized

cell-cell

interactions and concerted extracellular matrix remodeling. Maspin transfected prostate
and breast carcinoma cells showed decreased tumor invasion and motility in vitro.11 In
in vivo mouse models of breast, prostate and lung cancers, tumors derived from maspin
transfected cancer cells show decreased tumor growth and metastasis.11,33,36
Additionally, maspin-expressing tumors showed a decrease in in vivo angiogenesis.33,36
Re-expression or up-regulation of maspin has been shown to increase sensitivity to
drug-induced apoptosis in breast and prostate cancer cells.37-40
Evidence suggests that secreted maspin acts as a tumor suppressor. Using
recombinant maspin (rMas) to mimic secreted maspin, the Sheng laboratory has shown
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that purified exogenous maspin inhibits prostate tumor cell invasion and motility in
vitro.41,42 Furthermore, rMas acts at the cell surface to retard cell detachment by altering
the cellular distribution of phospho-FAK, and inhibit prostate tumor cell invasion and
motility

32

. Treatment of breast cancer cells with rMas decreased in vitro invasion

through basement membrane, which could be negated with anti-maspin antibody.43 It
was shown that subsequent internalization of rMas by breast cancer cells inhibits cell
motility through inhibition of Rac signaling and promote cell adhesion through
phosphoinositide 3-kinase (PI3K) signaling.44 Additionally, rMas has been shown to
exert an inhibitory effect on human umbilical vein endothelial cell (HUVEC) migration,
strengthen HUVEC adhesion, and inhibit neovascularization.17,36 The data generated
using rMas provides a basis for a tumor suppressive role of secreted maspin.
Consistent with the observation that maspin localizes to the nucleus, cytoplasm
and cell surface, maspin has been shown to interact with proteins in these subcellular
compartments. In the nucleus, maspin has been shown to inhibit histone deacetylase 1
(HDAC1) in the nucleus.34 In the cytoplasm, maspin has been shown to interact with
several proteins, such as interferon gamma 6 (IRF6), heat shock protein 90 (hsp90) and
glutathione-S-transferase  (GST).45,46 At the cell surface, extracellular maspin blocks
the pericellular proteolysis mediated by urokinase plasminogen activator (uPA) at the
cell surface of prostate cancer cells.41,42 Interestingly, maspin partitions to those
subcellular compartments despite the absence of any specific signal sequence.
Therefore, the tumor suppressive activity of maspin may depend on maspin’s
subcellular localization and binding partners.
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Maspin may function as a tumor suppressor through its inhibition of the activation
of uPA, whose activation can initiate a proteolytic cascade by activating plasminogen to
generate plasmin, a serine protease that activates many proteases and degrades nonfibrillar extracellular matrix (ECM). Urokinase plasminogen activator is secreted as an
inactive zymogen, pro-uPA, which binds to its cell surface-anchored receptor, urokinase
plasminogen activator receptor (uPAR), and undergoes specific proteolytic cleavage
into an active two-chain serine protease. Extracellular uPA may remain bound to uPAR
or may dissociate to become a soluble protein. Maspin was shown to have an affinity for
uPAR-bound uPA, but not soluble uPA.41,42 Furthermore, maspin has greater affinity for
pro-uPA over active uPA.32 Binding between maspin and uPA was shown to occur via
their exosites.47 Given that pro-uPA has been shown to act as a signaling ligand,
maspin’s interaction with pro-uPA may result in greater inhibiting capacity than maspin’s
interaction with uPA. Maspin has been shown to promote internalization of the
uPA/uPAR complex via low density lipoprotein receptor-related protein-1 (LRP-1), which
maybe one mechanism by which maspin may prevent ECM degradation and the
proteolytic cascade as a tumor suppressor.32
High uPA expression is associated with a low disease-free and overall survival
rate among breast cancer patients.48 The tumor-promoting activity of uPA seems to
depend on its ability to activate plasminogen, leading to the generation of plasmin. In
addition to maspin, plasminogen activator inhibitor type I (PAI-1) is an inhibitor of uPA
Interestingly, PAI-1 is up-regulated in many types of cancer and is associated with a low
disease-free and overall survival rate. Maspin however is associated with better overall
survival in many cancer types. Of note, uPA and its proteolytic target, plasmin, do not
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directly cleave the fibrillar collagen matrix. However, they may degrade newly
synthesized pro-collagen prior to its assembly into the fibrillar matrix. Additionally,
maspin may prevent collagen I degradation by inhibiting uPA-mediated activation of
plasminogen and, thus, pro-collagen I degradation.
The tumor suppressive activity of maspin in the nucleus may occur, in part,
through inhibition of HDAC1, which was identified as an interacting partner of maspin
through a yeast two-hybrid screen.34 The Sheng laboratory has shown that maspinmediated inhibition of HDAC1 leads to epigenetic changes and renewed expression
signatures for a better-differentiated phenotype.34,35,49,50 Of the genes down regulated,
many were pro-tumor and of the genes up regulated, many were antitumor. Also, our
lab has shown that a single point mutation of the aspartate to glutamate in the KDEL
sequence (amino acid residue 346) resulted in a predominantly nuclear localization and
stronger HDAC1 inhibition in comparison to the wild-type maspin.14 Consistently, forced
exclusion of maspin from the nucleus, using a nuclear exclusion signal, diminishes
maspin-mediated inhibition of growth and metastasis of breast cancer cells.51 Thus far,
maspin is the only identified endogenous polypeptide inhibitor of HDAC1. Maspin’s
interaction with HDAC1 may be a mechanism by which nuclear maspin acts as a tumor
suppressor.

Clinical Studies on Maspin’s Expression
Using NCBI GEO microarray database, the Sheng laboratory observed that
maspin mRNA expression was the highest in prostate hyperplasia and lowest in primary
prostate cancers during tumor progression (unpublished data). At the protein level,
maspin expression is up-regulated in pre-neoplastic lesions, which is consistent with the
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NCBI GEO data.29 Additionally, during tumor progression, the nuclear/cytoplasmic
balance first shifts to a greater cytoplasmic expression.29,52,53 Eventually, maspin
expression

is

down

regulated

and

often

lost

in

invasive

and

metastatic

carcinomas.11,29,52 Maspin expression predicts a better prognosis for many cancers. Of
note, high nuclear expression of maspin in patients showed better prognosis in
comparison with high cytoplasmic maspin expression.52,54,55 For example, nuclear
expression of maspin is associated with a lower recurrence rate in squamous cell
carcinoma of the larynx.56
Exceptions were reported with ovarian, gastric and thyroid cancers, where
maspin expression correlates with a poor prognosis. In ovarian cancer, although overall
survival was worse in patients with maspin expression, survival was greater when
maspin is localized to the nucleus than when maspin is localized to the cytoplasm.54
Similarly, in gastric cancers, patients with nuclear maspin showed better response to
drug treatment with better overall survival than patients with cytoplasmic expression,
although overall survival was worse in patients with maspin expression.57 Strong
cytoplasmic and weak nuclear maspin expression has also been noted in pancreatic
cancer tissue specimens.58,59 In contrast to other cancers, nuclear staining of maspin
was not associated with better prognosis in pancreatic cancers, yet tissues with nuclear
maspin staining were better differentiate.59 In thyroid cancer, there are conflicting
reports correlating maspin expression with prognosis. Bal et al (2008) reported strong
cytoplasmic expression of maspin and completely negative nuclear expression of
maspin in immunohistological stains of thyroid tissues.60 The strong cytoplasmic
expression of maspin was correlated with an adverse prognosis.
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Interestingly, maspin is weakly expressed or not expressed in the normal tissues
of the ovaries, pancreas and thyroid, yet maspin expression is high, and mostly
cytoplasmic, in the tumor tissue.54,58,60-62 Maspin may serve as an adverse prognostic
indicator for ovarian, pancreatic and thyroid cancers.54,63 The prognostic differences of
maspin among cancers may reflect the cell origins of the tumor.

The Enigmatic Secretion of Maspin
Although one report described evidence that maspin is localized exclusively to
the intracellular compartment

64

, the compilation of published data highlights a majority

consensus that maspin can act extracellularly to exert tumor suppressor activity. Upon
initial discovery, immunohistochemical analysis revealed maspin protein within the
luminal ducts of breast tissue, suggesting that maspin is secreted.11 Additionally,
maspin was reported to partition into secretory vesicles.61 Maspin has been consistently
detected in the conditioned media (CM) of maspin-expressing cells of normal and tumor
breast, prostate and lung origin. Furthermore, extracellular maspin has been
demonstrated to have anti-tumor effects.32,42,65,66 Secreted maspin from maspin
transfected prostate cancer cells inhibited degradation of collagen I (Col I).33 Secreted
maspin, derived from the CM of normal myoepithelial cells, was shown to inhibit breast
carcinoma invasion without an effect on proliferation.65 Secreted maspin was shown to
exhibit anti-invasive and anti-angiogenic activity.66,67 Either the addition of a maspin
antibody into the CM or the depletion of maspin from the CM was able to abrogate
invasion. The Sheng laboratory demonstrated that maspin associates with the
uPA/uPAR complex at the cell surface, which may inhibit pericellular proteolysis.42
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Taken together, the previous data suggest that secreted maspin acts in a paracrine
manner to inhibit invasion and metastasis (regulate the tumor microenvironment).
The mode of maspin secretion is enigmatic because maspin’s genetic sequence
does not contain a hydrophobic N-terminal secretory signal peptide (SSP), which is an
important feature for classical secretion of proteins.11 Classical secretion requires an
hydrophobic SSP at the N-terminus of the protein and are dependent on the
endoplasmic reticulum (ER)-Golgi secretory pathway for expulsion from the cell.68
Proteins with the SSP are trafficked to the ER and through the Golgi apparatus,
packaged into secretory vesicles and are then secreted when the secretory vesicles
fuse to the plasma membrane. The SSP is sequence motif that is analogous to an
address that directs the protein to its destination. Each organelle has a specific
sequence motif that directs proteins to that organelle. The location of the motif on the
protein is also unique to that motif. For example, the SSP motif is located at the Nterminus of ER-Golgi dependent secreted proteins. Proteins without a localization signal
sequence become cytoplasmic proteins by default. Not all secreted proteins contain the
SSP and do not depend on ER-Golgi secretion pathway for expulsion from the cell.
Secreted proteins that lack the SSP rely on non-classical secretory pathways, such as
microvesicle shedding, exosome secretion, or direct translocation across the plasma
membrane.

Exosomal Maspin: A New Frontier for the Tumor Suppressor
Interestingly, maspin has been reported as cargo of the exosomes, which
highlights one of the secretion mechanisms of maspin. Maspin has been reported in the
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exosomes of irradiated H460 lung adenocarcinoma cells, and maspin was absent from
exosomes of the control cells (non-irradiated H460 lung adenocarcinoma cells).69 In
another publication, maspin was present in the exosomes of undifferentiated
keratinocytes and absent in differentiated keratinocytes.70 However, the authors
reported the apparent molecular weight of maspin as 25 kDa in their proteomic analysis,
instead of 42 kDa, which is the molecular weight of maspin.
The exosomes are cholesterol-rich and sphingomyelin-rich bilayer vesicles. They
are packaged with biologically active mRNA, miRNA and proteins.71-73 Additionally, DNA
has also been identified in exosomes.74,75 The exosomes range from 30 – 120 nm in
size and are secreted upon the fusion of the endosomes to the plasma membrane.71,73
The biogenesis of the exosomes starts with the formation of intraluminal vesicles (ILVs)
from the invagination of the limiting membrane of the endosome.76 The ILVs are termed
exosomes once they are released into the extracellular space.
Interestingly, ILVs can fuse back to the endosome membrane, which is termed
back-fusion. ILV formation, scission and back-fusion occur through endosomal sorting
complexes required for transport (ESCRT) protein activity.77 The ESCRT proteins also
participate in the recruitment of cargo to the ILVs. The ESCRT proteins that are
responsible for recruitment of cargo recognize ubiquitinated proteins.77,78 Once
encapsulated, proteins are de-ubiquitinated by de-ubiquitinating ESCRT proteins. If
maspin is a bona fide cargo of the exosome, then the recruitment of maspin may
depend on a particular set of ESCRT proteins.
Exosomes have been shown to mediate paracrine signaling. The mechanisms
are unclear but there are three different hypotheses.79 One hypothesis highlights the
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receptor mediated interaction at the cell surface. Exosomes contain transmembrane
proteins, as well as luminal proteins. Some of the transmembrane proteins may act as
ligands that interact with cell surface proteins to initiate cell signaling. Another
hypothesis focuses on the endocytosis of exosomes. Endocytosis of the exosomes may
be initiated when the exosome docks to the cell surface. The exosomes may have
certain transmembrane proteins for docking to the cell surface. It is also hypothesized
that the exosomes may fuse to the plasma membrane. The exosome, like the plasma
membrane, is a lipid bilayer. As a structure formed from the endosome limiting
membrane, the exosome ultimately has a plasma membrane origin.
Exosomes are secreted by many cell types, such as immune cells, stem cells,
endothelial cells and cancer cells.80-83 Initial reports of exosomes claimed exosomes
expelled unwanted cellular material.84 Now, it is clear that exosomes are involved in
important cellular physiology. As secreted extracellular vesicles, the exosomes can be
used in paracrine signaling to regulate various biological processes. The function of the
exosome depends on the molecular content, which is determined by the cell of origin.
Under normal physiology, the exosomes have been shown to regulate biological
processes, such as reticulocyte maturation, modulation of T cell signaling during
pregnancy, and reprogramming hematopoietic progenitors.85-87 In certain diseased
states, exosomes have been shown to functions as positive mediators for processes,
such as cardiac repair.88 Exosomes may have prognostic value in evaluating
preeclampsia during pregnancy.89 Exosomes have also been shown to induce cytokine
secretion in macrophages.90 Exosomes may serve as prospective diagnostic markers of
different diseased states, such as Alzheimer disease and ischemia/reperfusion.91,92
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Furthermore, the exosomes may target either the local microenvironment or the distant
microenvironment.79

Exosomes in Cancer
Tumor-derived exosomes have been shown to function as negative mediators to
promote tumor activity, such as enhancing endothelial cell migration, promoting immune
cell evasion, priming the metastatic niche, and increasing angiogenesis.93-99 Melanomaderived exosomes were shown to educate bone marrow progenitor cells toward prometastatic phenotype.93 Prostate cancer-derived exosomes were shown to mediate
CD8+ T-cell apoptosis.94 CD8+ T cells can also be induced to suppress immune
response by CD4+ T cell-derived exosomes.100 Transport of miR-150 monocyte-derived
exosomes was shown to enhance endothelial cell migration.95 CD81+ exosomes
secreted by cancer-associated fibroblasts were shown to stimulate breast cancer cell
protrusive activity, motility and metastasis.97 Tumor-derived exosomes were shown to
communicate with immune cells to induce immune suppression.99,101 Tumor cells were
shown to respond to an acidic environment by increasing the secretion of exosomes.102

Hypothesis
To understand how different forms of secreted maspin may contribute to tumor
suppression, it is critical to understand how maspin is regulated at the step of trafficking.
The focus of my dissertation is to understand how maspin trafficking is regulated and
how exosomal maspin affects tumor cell biology. The central hypothesis states that
exosomal maspin may contribute to the tumor suppressive activity and may be

16
differentially regulated during tumor progression. In order to address the hypothesis, two
specific aims were developed. Specific Aim 1 is to investigate the differential regulation
of exosomal maspin in non-malignant cells and tumor cells. Specific Aim 2 is to
investigate the biological function of exosomal maspin in the microenvironment. The
results may provide novel insights into how the tumor microenvironment can be
modulated with maspin-based therapies.

17
Chapter 2: Materials and Methods
Cell Lines, Cell Culture Media and Antibodies
The CRL2221 cell line is a non-malignant prostate cell line. The LNCaP cell line
is a locally metastasized prostate cancer cell line collected from the lymph node. The
PC3 cell line is a metastasized prostate cancer cell line collected from the bone. The
MCF10A cell line is a spontaneously immortalized breast cell line. The SUM149 is a
triple negative breast cancer cell line lacking the estrogen receptor (ER), progesterone
receptor (PR) and Her2 receptor. The SUM159 is breast cancer cell line that does not
express maspin. The BEAS-2B cell line is a non-malignant lung cell line. The NIH 3T3
mouse fibroblast cells are non-malignant stromal cells and were a gift from Dr. HyeongReh Kim. CRL2221, PC3, LNCaP and BEAS-2B were purchased from American Type
Culture Collection (Manassas, VA). The MCF10A cell line was a gift from Dr. Fred
Miller. The SUM149 and SUM159 breast cancer cell lines were a gift from Dr. Stephen
Ethier. LNCaP and PC3 cell cultures were maintained in RPMI 1640 medium
supplemented with 5% v/v fetal bovine serum (FBS), 100 U/mL penicillin, 100 μg/mL
streptomycin, L-glutamine (L-Glu; 2 mM), Hepes (10 mM), NaHCO3 (1.5 mg/mL) and
non-essential amino acids (NEAA; 1 mM). CRL2221 cell cultures were maintained in
keratinocyte serum-free medium (KSFM) supplemented with 100 U/mL penicillin and
100 μg/mL streptomycin; additional supplements were provided with the KSFM. The
MCF10A and NIH 3T3 cell cultures were maintained in DMEM/F-12 medium
supplemented with 5% v/v FBS, L-Glu (2 mM), 100 U/mL penicillin,100 μg/mL
streptomycin, amphotericin B (0.5 µg/mL), cholera toxin (100 ng/mL), hydrocortisone
(HC; 1 µg/mL), epithelial growth factor (EGF; 10 ng/mL), and insulin (5 µg/mL). SUM149
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and SUM159 cell cultures were maintained in Ham’s F-12 medium supplemented with
10% v/v FBS, 100 U/mL penicillin,100 μg/mL streptomycin, insulin (5 µg/mL), and HC (1
µg/mL). BEAS-2B cell cultures were maintained in LHC-8 medium supplemented with
100 U/mL penicillin and 100 μg/mL streptomycin.
The stable transfected cell lines, Neo and M7, were derived, by our laboratory,
from the DU145 cell line, which is a metastasized prostate cancer cell line collected
from the brain. The DU145 cells were purchased from American Type Culture Collection
(Manassas, VA). Neo was transfected with an empty vector. M7 was transfected with a
plasmid containing maspin. Neo and M7 cells are maintained in RPMI 1640
supplemented with 5% v/v fetal bovine serum, NaHCO3 (1.5 mg/mL), G418/geneticin
(0.3 mg/mL), 100 U/mL penicillin,100 μg/mL streptomycin, L-Glu (2 mM), Hepes (10
mM), and NEAA (1 mM).
All cell growth media, L-Glu, penicillin-streptomycin, Hepes, NEAA, and EGF
were purchased from Life Technologies (Gaithersburg, MD). G418, NaHCO3, insulin,
hydrocortisone, amphotericin B and cholera toxin were purchased from Sigma-Aldrich
(St. Louis, MO). All cell cultures were cultured in a humidified incubator at 37 °C with
5% CO2.
Maspin mouse monoclonal antibody was purchased from BD Biosciences (San
Jose, CA). Tsg101 mouse monoclonal antibody, LAMP-2 mouse monoclonal antibody,
β-tubulin rabbit polyclonal antibody, PARP mouse monoclonal antibody, and GAPDH
mouse monoclonal antibody were purchased from Abcam (Cambridge, MA). Alix mouse
monoclonal antibody and Hsp90 rabbit polyclonal antibody were purchased from Santa
Cruz Biotechnology (Dallas, Texas). Ribosomal L26 mouse monoclonal antibody and
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Hsp70 rat monoclonal antibody were purchased from Cell Signaling (Danvers, MA).
Anti-mouse secondary antibody and anti-rabbit polyclonal secondary antibody were
purchased from GE Healthcare (Buckinghamshire, UK).

Exosome Isolation
Cells were cultured in 10 mm cell culture dishes. At seventy percent confluence,
culture media was removed and cells were washed thrice with PBS. Cells were
incubated in defined keratinocyte serum-free media (DKSFM) purchased from Life
Technologies (Gaithersburg, MD) supplemented with 100 U/mL penicillin, 100 μg/mL
streptomycin; additional supplements were provided with the DKSFM. After 24 h, the
conditioned media (CM) was collected and centrifuged at 4,000 x g for 10 min, at room
temperature, to pellet dead cells and cell debris. The supernatant (CM) was
concentrated with 15 mL Millipore 10 kDa centrifugal filter units (Darmstadt, Germany)
until the CM reached the desired volume of 1 mL (100X concentrated). The CM was
collected and centrifuged at 16,000 x g for 30 min at 4 °C to deplete the CM of high
molecular weight microvesicles. To isolate exosomes, the CM was centrifuged at 4 °C
and 100,000 x g for 24 h. The supernatant was saved and labeled vesicle-depleted
conditioned media (VDCM). The protein concentration of the VDCM was measured. The
pellet (exosomes) was washed twice by re-suspending exosomes in PBS and
centrifuged at 200,000 x g for two hours at 4 °C. For immunoblot analysis, the exosomal
proteins were resolved on 10% SDS-PAGE gel. For cell viability and motility assay,
exosomes were re-suspended in 1 mL of DKSFM supplemented with 100 U/mL
penicillin, 100 μg/mL streptomycin.
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Atomic Force Microscopy (AFM)
Atomic force microscopy imaging was conducted using Multimode IIIa (Digital
Instrument) and Dimension 3100 (VEECO). Exosomes were re-suspended in 50 µL of
PBS after isolation. Twenty microliters of exosomes were immobilized on cleaved mica
for detection. Briefly, 50 µL of 10 mM manganese chloride solution was incubated on
cleaved mica (1 cm x 1 cm) for 30 s. Excess manganese chloride was removed by
blowing dry with filtered compressed air. The exosomes were placed on mica and
incubated for 2 min, followed by rinsing (with ddH2O) and drying with filtered
compressed air. To image exosomes, tapping mode in air was performed using silicon
probes (Vistaprobe) with a nominal radius of curvature of 10 nm and cantilever spring
constant of 48 N/m as provided by the manufacturer. The surface was imaged
continuously at an average rate of 1−2 Hz on a 1×1−5×5 μm 2 area. The ranges of
frequency, amplitude, integral, and proportional gains used were 7.5-8.5 kHz, 0.5−1 V,
0.5−2, and 0.75−3 respectively. All AFM images were analyzed using Nanoscope
software version 5.12b (VEECO). Grade 5 muscovite mica was purchased from Ted
Pella and hand cleaved just before use. Manganese chloride (99%) was purchased
from Sigma-Aldrich (St. Louis, MO).

Dynamic Light Scattering (DLS) for Size Distribution and Zeta Potential
The size of the exosomes was measured by dynamic light scattering in terms of
hydrodynamic diameter (DH) with the Nanosizer ZS purchased from Malvern
Instruments (UK). Briefly, exosomes were re-suspended in 50 µL of PBS after isolation
and transferred to a low-volume, quartz microcuvette (ZEN0040, Malvern instrument).
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The backscattering angle Θ was fixed at 172° with a laser wavelength λ = 633 nm. The
size measurement range was from 1 nm to 6 μm. DH is a function of the diffusion
coefficient (D), temperature (T), and viscosity (η) according to the Stokes-Einstein
equation: DH 

kT , where k is Boltzmann constant and T is the temperature at 25 °C.
3 D

D is obtained from autocorrelation function via the cumulant fitting. For measuring the
surface charge, exosomes were re-suspended in 1 mL of PBS. The zeta potential of the
exosomes was measured with a combination of laser Doppler velocimetry and phase
analysis light scattering in a disposable capillary cell (DTS1070, Malvern Instrument).

Electron Microscopy
MCF10A derived exosomes were isolated and re-suspended in primary fixative
(4% v/v paraformaldehyde in 0.1 M sodium phosphate buffer). Exosomes were
incubated for 24 h in primary fixative. Then, 5 µL of exosomes were allowed to adsorb
onto carbon-coated, 400 mesh, nickel grids purchased from Electron Microscopy
Sciences (Hatfield, PA). After adsorption, the exosomes were incubated in either 0.3%
saponin or Tween-20 diluted in PBS for permeabilization. Exosomes were washed once
with PBS and thrice with glycine. Afterward, the exosomes were incubated in blocking
buffer (1% w/v cold-water fish gelatin in PBS) for 45 min. For primary antibody labeling,
exosomes were incubated for 1 h in 1:10 dilution of maspin, Tsg101 or mouse IgG. After
washing with 0.1% cold-water fish gelatin six times, exosomes were incubated in 1:10
dilution of conjugated gold mouse secondary antibody for 30 min. Exosomes were
washed six times in PBS followed by incubation in 1% v/v glutaraldehyde in 0.1M
phosphate buffer for 30 min. Then, the exosomes were washed in ddH2O. Negative
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staining was conducted in 2% uranyl oxalate (pH 7.0) for five minutes. The exosomes
were quickly rinsed once in ddH2O and allowed to air dry. Of note, incubations and
washings were carried out by transferring the grids with adsorbed exosomes onto
droplets of solutions/buffers. Exosomes were visualized using the JEOL 2010 FasTEM
instrument at 200 kV.

Immunoblot
Lysate: Cells were washed with PBS and incubated in 0.25% trypsin purchased
from Life Technologies (Gaithersburg, MD). Detached cells were re-suspended in the
appropriate media and pelleted by centrifugation at 2,000 x g for 5 min. Cells were resuspended in PBS and pelleted again by centrifugation at 2,000 x g for 5 min. Cells
were lysed with cold RIPA lysis buffer (20 mM Hepes, 100 mM NaCl, 0.1% SDS, 1%
NP-40/IGEPAL-CA630, 1 mM deoxycholic acid, 1 mM Na3VO4, 1 mM EGTA, 50 mM
NaF, 10% Glycerol, 1X Protease Inhibitor Cocktail, 1 mM EDTA). Cell lysates were
collected, as the supernatant, by centrifugation at 16,000 x g for 30 min at 4 °C. Protein
concentration was measured using the Pierce/ThermoScientific BCA Protein Assay
Reagent Kit (Rockford, IL). Proteins were resolved on 10% SDS-PAGE and, then,
transferred overnight to a PVDF membrane using electrophoresis. The membrane was
incubated in blocking buffer (5% nonfat dry milk in PBS with 0.1% Tween-20) for one
hour and incubated in a 1:1000 dilution of primary antibody overnight. The membrane
was washed and incubated in a 1:5000 dilution of secondary antibody for 1 h followed
by washing. Membranes were developed on film for visualization of proteins.
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Conditioned media (CM) and Vesicle-depleted Conditioned Media (VDCM):
The conditioned media was isolated and concentrated as described in “Exosome
Isolation” section. Conditioned media, in which microvesicles were removed, were
termed “vesicle-depleted CM” (VDCM). Protein concentration was measured. Proteins
of the CM were processed for immunoblot as described for lysate proteins.

Isolation of Cytoplasmic Ribosomes (Polysomes)
CRL2221 cells were cultured in 10 mm cell culture dishes. At seventy percent
confluence, cells were collected with trypsin. Briefly, cells were incubated in 0.25%
trypsin for 1 min. Detached cells were pipetted into 1.5 mL collection tubes and
centrifuged at 2,000 x g for 5 min. Trypsin was removed by aspiration and cells were resuspended in PBS. Cells were washed by centrifugation at 2.000 x g for 5 min. Cells
were re-suspended in cold homogenization buffer (40 mM Tris pH 7.4, 50 mM KCl, 10
mM MgCl2, 3 mM DTT, and 0.5 mg/ml heparin) and transferred to a 3 mL Dunce
homogenizer. Cells were lysed using a Dounce homogenizer for 1 min on ice. Lysates
were centrifuged at 4 °C and 16,000 x g to remove the nuclei and mitochondria from the
homogenates. Then, the lysates were centrifuged at 4 °C and 100,000 x g to remove
microsomes (rough endoplasmic reticulum; RER) from the homogenates. 500 µL of the
supernatant was layered over a discontinuous sucrose gradient containing 1 ml each of
1.0 M (top), 1.5 M, 2.0 M and 2.5 M (bottom) sucrose in polysome buffer. The
supernatant was centrifuged at 4 °C for 2 hours at 100,000 x g. After centrifugation, 500
µL fractions were collected starting at the bottom (2.5 M sucrose). Thirty microliters of
the fractions were mixed with sample buffer and loaded into the wells of a 10% SDS-
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PAGE gel. Proteins were resolved and transferred by electrophoresis to a PVDF
membrane for immunoblot analysis.

Immunofluorescence Labeling
The CRL2221 cells were seeded at a density of 4,000 cells/mL and incubated in
an 8-well chamber slide purchased from Thermo Fisher Scientific (Hudson, NH). After
24 h, the media were removed and cells were washed twice with PBS. The cells were
then incubated in 4% paraformaldehyde for 15 min followed by methanol fixation for 10
min at -20 °C. Cells were incubated with 1% Triton-X 100 and then with 10% normal
goat serum in PBS for 1 hr. The cells were incubated in 1:100 maspin primary antibody
and 1:100 LAMP-2 primary antibody. Cells were washed and incubated for 1 h in 1:500
dilution of Alexa Fluor 488 and Alexa Fluor 594 fluorescent secondary antibodies. The
nucleus was stained with 4´,6-diamidino-2-phenylindole (DAPI) for 1 min. Cells were
visualized under a LSM-510 confocal microscope at 400X magnification.

Secretion-Targeted Drug Treatments
The CRL2221 cells were cultured in 10 mm cell culture dishes until seventy
percent confluence. Cells were washed thrice with PBS. Cells were incubated for 24 h
in DKSFM with or without brefeldin A (BFA), ionomycin (IONO, methylamine (MA), or
chloroquine (CQ) at the concentrations indicated in the figure legends. After 24 h, the
CM was removed and saved for immunoblot analysis. In order to determine whether the
drug treatments affected trafficking of exosomal maspin, the media were removed and
processed for the isolation of the exosomes from the CM as described in the “Exosome
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Isolation” section. The cells were washed and collected after incubation with 0.25%
trypsin. The cell lysates, exosomes and VDCM were processed for immunoblot analysis
as described in the “Immunoblot” section. The VDCM was also used for zymography as
described in the “Zymography” section. Drugs were purchased from Sigma-Aldrich (St.
Louis, MO).

Zymography
CM (containing exosomes) and VDCM (depleted of exosomes) were collected
from CRL2221 cells treated for 24 h with or without BFA, IONO, MA, or CQ in DKSFM.
The drug concentrations are indicated in the figure legends. The CM was concentrated
using 15 mL Millipore 10 kDa centrifugal filter units. Twenty microliters of CM was
diluted with β-mercaptoethanol free sample buffer and loaded onto a zymogram gel.
Proteins were resolved by electrophoresis. Recombinant matrix metalloprotease 9
(MMP9), gifted by Dr. Rafael Fridman, was loaded onto the zymogram gel as a positive
control. Following electrophoresis, the gel was incubated in re-naturing buffer (2.5%
Triton X-100 in ddH2O) for 30 min. Then, the gel was washed in ddH2O for 10 min. The
gel was transferred to developing buffer (50 mM Tris 9, pH 8.0), 5 mM CaCl2, 200 mM
NaCl, and 0.02% v/v Brij-35) and incubated for 30 min. The developing buffer was
replaced with new developing buffer and incubated at 37 °C for at least 16 hours. The
gel was stained in 0.5% w/v Coomasie blue solution (Coomasie blue brilliant R-250 in
5% v/v acetic acid, and 10% v/v methanol) and incubated at room temperature with
gentle shaking for 30-60 min. The gel was then incubated in de-staining solution (5% v/v
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acetic acid and 10% v/v methanol in ddH2O) until bands were visualized. Images of the
zymogram gel were captured using Bio-Rad Gel Doc XR+ system (Hercules, CA).

Membrane Stripping Assay
To remove peripheral proteins at the membrane surface, pelleted CRL2221derived exosomes were re-suspended and washed twice with 12.5 mM, 25 mM, 50 mM
or 100 mM KCl in PBS at 4 °C and 100,000 x g for 2 h. The control (no KCl) was resuspended and washed twice in PBS at 4 °C and 100,000 x g for 2 h. The supernatant
was removed and the exosomes were washed two additional times with PBS at 4 °C
and 100,000 x g for 2 h to remove residual KCl. For immunoblot analysis, the exosomes
were re-suspended in 1X sample buffer after the final wash, and the exosomal proteins
were resolved on 10% SDS-PAGE gel and transferred to PVDF membrane.

Maspin Knockdown and Stable Transfection
Stable transfected MCF10A cells lines were established with the pGIPZ shRNAmir lentiviral plasmid system (Thermo Scientific, Asheville, NC) according to the
manufacturer’s instructions. Briefly, MCF10A cells were seeded in 10 mm cell culture
plates. At fifty percent confluence, cells were

transfected with either a mixture of

maspin shRNA plasmids (RHS4430-98895314, RHS4430-99297939, RHS443099139485) or the noncoding shRNA plasmid (RHS4346) using the X-treme GENE 9
DNA transfection reagent (Roche Applied Science, Indianapolis, IN) according to the
manufacturer’s instructions. Stable transfected clones were selected with 10 μg/mL
puromycin. The clones were maintained in DMEM/F-12 medium containing 5% FBS. To
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verify maspin knockdown, cell lysates of maspin knockdown clones and noncoding
clones were processed for immunoblot analysis as described in the “Immunoblot”
section.

Exosome Labeling
Exosomes were isolated as described in the “Exosome Isolation” section. After
the centrifugation at 100,000 x g, the exosomes were washed once with PBS and
labeled with the PKH26 Red Fluorescent Cell Linker Kit (Sigma Aldrich) according to the
manufacturer’s protocol. The exosomes were centrifuged at 100,000 x g to remove
excess PKH26 and re-suspended in 1 mL of DKSFM. The NIH 3T3 mouse fibroblast
cells were incubated in a 1:100 dilution of labeled exosomes for 24 h. Live cell imaging
of NIH 3T3 cells after exosome treatment was performed using the Leica Fluorescence
microscope.

Cell Viability Assay
Drug Treatment: The CRL2221 cells were seeded into 96-well plates at a
density of 20,000 cells/mL and allowed to attach to the plate for 24 h. The CRL2221
cells were treated with or without BFA, IONO, MA or CQ at the concentrations indicated
in the figure legends (Figures 4 and 9) for 24 h. Cell viability was assessed with the
WST-1 Reagent (Roche Diagnostics) according to the manufacturer’s instructions. All
drugs were purchased from Sigma-Aldrich (St. Louis, MO). For statistical analysis, one
way analysis of variance (ANOVA) was performed using the SigmaPlot software
(Chicago, IL).
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Exosome Treatment: Cell viability of the NIH 3T3 cells was assessed after
treatment with various concentrations of the exosomes as indicated in figure 13. The
NIH 3T3 cells were seeded at 20,000 cells/mL in 96-well plates. Cells were allowed to
attach to the plate for 24 h. The exosomes were isolated as described in “Exosome
Isolation” section. The exosomes were re-suspended in 1 mL of DKSFM and dilutions of
isolated exosomes were prepared from the suspended exosomes. Then, cells were
treated for 24 h with or without exosomes derived from the MCF10A stable transfected
clones. WST-1 Reagent

(Roche Diagnostics) was added according to the

manufacturer’s instructions.

Cell Lysis (LDH Assay)
The CRL2221 cells were seeded into 96-well plates at a density of 20,000
cells/mL and allowed to attach to the plate for 24 h. The CRL2221 cells were treated
with or without BFA, IONO, MA or CQ at the concentrations indicated in the figure
legend (Figures 4 and 9) for 24 h. 100 µL of the conditioned media of the CRL2221 cells
were transferred to a new 96-well plate. Lactate dehydrogenase (LDH) cytotoxicity
assay was used to assess LDH activity according to the manufacturer’s instructions.
The LDH cytotoxicity assay was purchased from Cayman Chemical (Ann Arbor, MI). For
statistical analysis, one way analysis of variance (ANOVA) was performed using the
SigmaPlot software (Chicago, IL).
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Motility Assay
NIH 3T3 cells were seeded into 6 well plates and allowed to attach to the plate
for 24 h. The exosomes were re-suspended in 1 mL of PBS and administered to the
NIH 3T3 cells at a dilution of 1:100 dilution. The NIH 3T3 cells were treated with the
exosomes for 24 h. NIH 3T3 cells were collected and seeded into the chambers of
Corning transwell plates (Sigma-Aldrich). Motility was assessed after 24 h. For
statistical analysis, one way analysis of variance (ANOVA) was performed using the
SigmaPlot software (Chicago, IL).

Quantitative Real Time-PCR (qRT-PCR)
Total RNA was isolated using the Qiagen RNeasy Mini kit (Valencia, CA,). The
RNA was converted to cDNA using the Bio-Rad iScript cDNA synthesis kit (Irvine, CA).
The mRNA levels of the following genes were quantified using the indicated forward and
reverse primer pairs: GAPDH (forward: 5´ - ATC ACC ATC TTC CAG GAG CGA - 3´
and reverse: 5´ - GCC AGT GAG CTT CCC GTT CA - 3´); Vimentin (VIM ; forward: 5´ GCT CCT ACG ATT CAC AGC CA- 3´ and reverse: 5´ - CGT GTG GAC GTG CTG
ACA TA- 3´); uPA forward: 5´ - CAT CCA TCC AGT CCT TGC GT - 3´ and reverse: 5´ ACG CAT AC ACCT CCG TTC TG - 3´); α-smooth muscle actin (SMA; forward: 5´ GAG CCC AGG CAT TGC TGD CA - 3´ and SMA reverse: 5´ - GAG GCG CTG ATC
CACA AA AC - 3´); p21 forward: 5´ - CAG GCA CCA TGT CCA ATC CT- 3´ and p21
reverse: 5´ - AAT CTG TCA GGC TGG TCT GC - 3´); collagen I (Col I; forward: 5´ TCT CCA CTC TTC TAG TTC CT- 3´ and reverse: 5´ - TTG GGT CAT TTC CAC ATG
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C - 3´). GAPDH was used as an internal reference for normalization. For statistical
analysis, ANOVA was performed using the SigmaPlot software (Chicago, IL).
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Chapter 3: Results

Chapter 3A: Investigating the Differential Regulation of Exosomal Maspin in NonMalignant Cells and Tumor Cells

Exosomes have distinct physical properties
The exosomes were isolated from a panel of maspin-expressing non-malignant
cells and tumor cell lines of the breast, prostate and lung. Then, the exosomes were
analyzed by atomic force microscopy (AFM) and dynamic light scattering (DLS) through
the collaboration with laboratory of Guangzhao Mao, Ph.D. at Wayne State University.
The height and amplitude (the first derivative of the height) were measured using AFM.
The images from AFM confirmed the isolation of the secreted nanoparticles from nonmalignant cells (Figure 1A) and tumor cells (Figure 1B). The nanoparticles were
spherical in morphology, which is consistent with the description of exosomes reported
in the literature.71 Additionally, the morphology of the exosome is described as cupshaped in some reports.103 In our hands, only a few of the nanoparticles visualized by
AFM seem to exhibit a cup shape. The original morphological description of the
exosomes was determined from electron microscopy (EM) images produced. Therefore,
it is unknown whether the cup shape is due to the EM preparation or if it is the bona fide
shape of exosomes. The data presented in Figure 1 show a representative visualization
of the exosomes by AFM. Heterogeneity of the exosomes was observed in the AFM
images, irrespective of the cell type, as well as some degree of aggregation. The
degree of aggregation seemed to vary among the cell lines. In addition, various
amounts of exosomes were observed in the AFM images. The amount of exosomes
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Figure 1 – The physical characteristics of the exosomes. Images were produced
using atomic force microscopy. (A) Representative images of exosomes derived from
non-malignant cell lines. (B) Representative images of exosomes derived from tumor
cell lines. Scale is 1 μm.
detected did not appear to differ between non-malignant and tumor cells. However,
there is not yet a reliable method to quantify exosomes because of their size. FACS
sorting has been used to try to quantify the number of exosomes, but requires antibody
linkage of the exosomes to magnetic beads, which may result in multiple beads
attaching to one exosome.104
Atomic force microscopy allowed the visualization of the exosomes but does not
provide quantitative data. In order to quantify the size of the exosomes, DLS was used
to measure the size distribution. DLS is advantageous in that it measures the size
distribution of particles that are in the nanometer range. The exosome fraction derived
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Table 1: Average Size Distribution of the Exosomes
Cell Type

Normal

Tumor

Cell Line

Size Distribution (± standard deviation)

n

CRL2221

53.6 ± 12.8; 367.6 ± 144.8

5

MCF10A

92.9 ± 42.4; 337.7 ± 60.4

7

BEAS-2B

41.2 ± 8.8; 305.0 ± 85.6

3

LNCaP

55.4 ± 5.3

4

PC3

87.2 ± 10.1

3

SUM149

91.1 ± 1.8

3

Figure 2 – Size distribution of exosomes measured by DLS. (A) Representative
graphs of exosomes derived from non-malignant cell lines. (B) Representative graphs
of exosomes derived from tumor cell lines.
from the non-malignant cell lines contained two populations of nanoparticles (Table 1
and Figure 2). The first population identified from the non-malignant cell line
corresponds to the reported size range of the exosomes. The second population
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identified from the non-malignant cell line is above the reported size range of the
exosomes. In contrast, the tumor cell lines secreted one population of nanoparticles that
were in the reported size range of the exosomes (Table I). Of note, the same exosome
preparations were used for DLS and AFM. Therefore, the more detailed physical
properties revealed by DLS were not due to variations in exosomal preparation.
MCF10A-derived exosomes were also visualized by electron microscopy, which
was conducted through a collaboration with Dr. James Granneman of Wayne State
University School of Medicine, Department of Psychiatry and Behavioral Neuroscience.
Consistent with the literature, the MCF10A-derived exosomes were spherical in shape
(Figure 3). A few exosomes exhibited the “cup” shape that has been described by some
of the literature (Figure 3A, left image, and 3C, left image). Of note, it is unknown
whether the “cup” shape is due to the preparation process for EM. The cup shape was
not observed in the AFM images of the exosomes. The exosomes were immunolabeled
with either maspin (Figure 3B) or Tsg101 (Figure 3C). Intact exosomes were observed
with a defined border. Maspin was not labeled in the intact exosomes. However, maspin
congregated in areas where the exosomes are not well-defined. This data suggest that
some of the exosomes may have been sensitive to the permeabilization process and
ruptured. The ruptured exosomes exposed the luminal proteins and maspin was easily
accessible. The intact exosomes may have not been permeabilized, which may be why
maspin was not detected in the intact exosomes. The Tsg101 was detected in intact
exosomes but also congregated in areas where the exosomes were less defined
(Figure 3C, middle and left images). There were also exosomes that did not contain
Tsg101 (Figure 3C, left image). Consistent with the AFM images, single particles and
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Figure 3 – Electron Microscopy of the exosomes. Representative images of the
MCF10A-derived exosomes. Exosomes were isolated and permeablized for
immunolabeling. (A) Exosomes were incubated with IgG control (B) Exosomes were
incubated in maspin primary antibody (C) Exosomes were incubated in Tsg101
primary antibody. 100 nm scale bar.
aggregated particles were detected in the exosome fraction. The data from the EM
images further support the speculation that the second peak detected in the normalderived exosome fraction is most likely due to a high degree of aggregation.

36
The exosomes of non-malignant cells and tumor cells were further analyzed by
DLS for membrane surface charge by measuring the zeta potential. The zeta potential
for the exosomes of all of the cell lines was negative (Table 2). Thus, exosomes across
various cell lines maintained an average negative membrane surface charge. Of note,
the zeta potential represents an average of the surface charge, which does not rule out
the possibility that positively charged exosomes exist. Given that the charge of a bilayer
membrane depends on the associated proteins, the consistent average negative
surface charge suggests that the exosomes of the cell lines share common
transmembrane and/or peripheral proteins.
Table 2: Average Zeta potential of the Exosomes
Cell Type

Normal

Tumor

Cell Line

Zeta Potential

n

CRL2221

-13.8 ± 0.666

3

MCF10A

-12.6 ± 1.85

3

BEAS-2B

-13 ± 0.907

3

LNCaP

-11.2 ± 0.611

3

PC3

-11 ± 0.681

3

SUM149

-11.7 ± 0.473

3

Maspin Trafficking and Secretion is Independent of the ER-Golgi
The primary sequence of maspin does not reveal an N-terminal secretory signal
peptide (SSP), which is necessary for ER-Golgi dependent (classical) secretion.
Therefore, maspin may be secreted by a non-classical mechanism. Software has been
developed to predict the chance of a non-classical secretion by a protein that lacks the
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Table 3: Prediction for Non-Classical Secretion of Maspin

SSP. Proteins with an NN-score above 0.5 are strongly predicted to be secreted by
a non-classical mechanism.105 Interestingly, maspin received an NN-score of 0.499 from
the software, which is 0.001 below the predictive threshold (Table 3). Maspin’s score
may be below the threshold due to the fact that maspin also functions as an intracellular
protein, which may not be taken into account by the software.
The secretion of a protein may depend on where the protein is synthesized and
what particular pathways are involved. Proteins that are secreted by the classical
secretory pathway are thought to be translated by the ribosomes on the rough ER
(RER), where they can be trafficked through the ER and Golgi apparatus for secretion68.
In contrast, non-classically secreted proteins are thought to be translated by the free
ribosomes. Maspin sequence lacks the SSP necessary for ER-Golgi dependent
secretion, which suggests that maspin is most likely translated by free ribosomes.
Ribosomes have the ability to translate mRNA to proteins when attached to or
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unattached to the rough ER (RER). Free
cytoplasmic

ribosomes

are

physically

identical to ribosomes attached to the RER
with identical translation efficiency.68 Free
ribosomes

mainly

translate

cytoplasmic

proteins and other intracellular proteins that
do not need the ER or Golgi for posttranslational processing. In concordance,
many of the non-classically secreted proteins
are cytoplasmic proteins.68 In order to
Figure 4 – Cytoplasmic ribosomes
translate maspin mRNA.
Cytoplasmic ribosomes were isolated
from lysates of the CRL2221 cells by a
sucrose density gradient. Proteins
were resolved on a 10% SDS-PAGE
for Western blot analysis.

determine whether maspin is translated by
the free ribosomes, the free ribosomes were
isolated from the cytoplasm and floated on a
sucrose density gradient for purification.

Fractions were collected from the gradient and proteins were detected by immunoblot
analysis (Figure 4). The free ribosome fraction (fraction 5) was verified with L26, a
ribosome marker. β tubulin was used as a positive control for cytoplasmic proteins.
Maspin was also detected in fraction 5, which suggests that maspin is translated in the
cytoplasm by free ribosomes (Figure 4).
To further investigate the trafficking of maspin, CRL2221 cells were treated with
BFA for 24 h. BFA targets retrograde transport from the Golgi to the ER, which causes
the intracellular accumulation of ER-Golgi dependent secretory proteins, such as matrix
metalloprotease 9 (MMP9). Treatment with BFA did not inhibit the secretion of maspin,
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Figure 5 – Maspin is not secreted through the ER-Golgi secretory pathway. (A)
Immunoblot analysis of lysates and CM from CRL2221 cells after 24 h treatment
with 18 µM of BFA. (B) Zymogram of the CM from CRL2221 cells after 24 h
treatment with 18 µM of BFA.
which suggests that maspin secretion occurs by an ER-Golgi independent mechanism
(Figure 5A). When compared to untreated cells, the secretion of maspin increased as a
result of BFA treatment. There was also a slight increase in intracellular maspin. The
increase in maspin in both lysates and CM may be due to general cellular stress caused
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by the treatment. Interestingly, maspin secretion has been shown to increase under
cellular stress conditions.106 MMP9 is secreted via the ER-Golgi secretory pathway and
the primary amino acid sequence of MMP9 contains an N-terminal SSP. Thus, MMP9
was used as a positive control to verify that BFA inhibited classical protein secretion.
The CM of both the CRL2221 cells and PC3 cells were assessed for MMP9 by
zymography. The secretion of MMP9, as detected by zymography, was significantly
inhibited by the treatment of BFA, which indicates that BFA inhibited ER-Golgi
dependent secretion (Figure 5B). In contrast, secreted MMP9 was detected in untreated
cells.
Confocal microscopy of the CRL2221 prostate cells revealed co-localization
between maspin and lysosome-associated membrane protein 2 (LAMP-2), a late
endosome and lysosome marker (Figure 6A, white arrows).107,108 Additionally, LAMP-2
has also been detected in the exosomes.102,108-110 The data suggest that maspin may be
trafficked to the late endosome, which is consistent with the notion that maspin is
associated with the exosomes. Of note, the CRL2221 cells are heterogeneous in
maspin subceullar localization, in which some cells have mostly nuclear maspin while
some cells have mostly cytoplasmic maspin. Figure 6B shows the subcellular
fractionation of a heterogeneous poopulation of CRL2221 cells. Unlike the normal tissue
epithelium, which has high nuclear maspin staining, the CRL2221 cells have more
cytosolic maspin. Our lab has also shown that maspin can be mostly localized to the
nucleus in CRL2221 cells.14 The difference in maspin nuclear:cytoplasmic ratio in the
CRL2221 cells may be due to unidentified variations in cell culture conditions.
Additionally, it is unknown whether maspin localization changes during certain cellular
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Figure 6 – Co-localization of maspin with the endo-lysosomal protein, LAMP-2. (A)
Representative confocal microscopy images of CRL2221 cells after immunolabeling with
maspin and LAMP-2 antibodies. Maspin co-localizes with LAMP-2 (white arrows). 400X
magnification. (B) Subcellular fractionation of CRL2221 cells.
states, such as cell cycle progression, or under certain processes, such as cell stress.
These unknown factors may contribute to the difference I observed in maspin
subcellular localization compared to what was previously reported. Of note, the
CRL2221 cells are an immortalized cell line. Clinical tissue samples consistently show
evidence of maspin nuclear localization in normal cells as discussed in the introduction.

Exosomal maspin in non-malignant cells and tumor cells
It is unknown how the level of maspin in the exosomes is regulated in response
to tumor progression. The exosomal cargo is recruited to the intraluminal vesicles (ILVs)
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Figure 7 – Exosomal maspin is secreted by non-malignant cells. Immunoblot
analysis of the lysates, VDCM and exosomes from non-malignant cells (CRL2221,
MCF10A and BEAS-2B) and tumor cells (LNCaP, PC3 and SUM149). Immunoblot
membranes were probed for various proteins that have been reported in the
exosomes. Alix and Tsg101 are markers of the exosome.
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during formation. Since maspin colocalizes with an endosome marker,
maspin may be recruited to the
exosome as a cargo protein. The
levels of maspin in the exosomes
isolated from the non-malignant cells
and
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membranes
Figure 8 – Loss of maspin expression
results in absence of exosomal maspin.
Immunoblot analysis of the lysates, VDCM
and exosome fractions of the CSC#2 lung
cancer cells. Tsg101 and Alix are markers of
the exosome.

cells

The

under

conditions
PVDF

overexposed

in

order to determine the presence of
maspin. As shown in figure 7, the nonmalignant cells (CRL2221, MCF10A
and BEAS-2B) contain high levels of

exosomal maspin. In contrast, the amount of exosomal maspin in the tumor-derived
exosomes (LNCaP, PC3, and SUM149) is reduced. Judging from the detection of the
exosomal markers, Alix and Tsg101, the exosomal preparation was highly enriched and
distinct from the vesicle-depleted conditioned media (VDCM). Interestingly, soluble
maspin was detected in the VDCM of the non-malignant cells. The absence of the
exosomal markers, Alix and Tsg101, and cellular (cytoplasmic) markers, GAPDH and
tubulin, from the VDCM validate that the VDCM was not contaminated with cellular or
vesicular components. Therefore, maspin’s expression in the VDCM was not due to
contamination. The level of soluble maspin was most abundant in the VDCM of the non-
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malignant cells. These data demonstrate that the isolation of the exosomal maspin does
not deplete maspin from the VDCM. In comparison, despite the expression of
intracellular and VDCM (by the tumor cells), little to no exosomal maspin was detectable
by the tumor cells. The evidence suggests that maspin is secreted by two mechanisms
that results in both a soluble protein and exosomal protein. Moreover, the presence of
both soluble maspin and exosomal maspin in the CM may indicate dual mechanisms of
secretion. The variation of exosomal maspin between non-malignant cells and tumor
cells indicate that the recruitment of maspin to the endosome and, subsequently, the
exosome may be differentially regulated in tumor progression.
Additionally, CSC#2, a cancer cell line developed from the BEAS-2B cells using
smoke condensate, was analyzed for exosomal maspin. The lysate, VDCM and
exosomes were isolated from the CSC#2. The proteins were resolved on the same gel
as the BEAS-2B fractions from figure 6 for immunoblotting on the same membrane. As
shown in figure 8, the CSC#2 does not express very much maspin in the lysate and
maspin is undetectable in the CM and exosome fractions. The data from this study
suggests that during tumor progression, exosomal maspin is lost even though the tumor
cells continue to express intracellular maspin and secreted soluble maspin, but not
exosomal maspin.

Re-expression of maspin in DU145 cells does not induce exosomal maspin
During tumor progression, maspin expression can be lost. Using the DU145
prostate cancer cell-derived M7 (maspin-expressing) and Neo (mock control) cell lines,
the Sheng laboratory has shown a tumor suppressive role for maspin at the step of
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tumor invasion, motility, metastasis, and
overall epithelial de-differentiation. In
the current study, exosomes were
isolated from the M7 cells and the Neo
cells in order to determine whether reexpression

induces

secretion

of

exosomal maspin. As expected, maspin
was detected in the lysate of the M7
Figure 9 – Maspin re-expression does
not induce exosomal maspin secretion.
Western blot analysis of the lysate, VDCM
and exosome from the Neo cells and the
M7 cells.

cells, but not in the lysate of the Neo
cells

(Figure

detected

in

9).

Maspin

was

not

either

the

VDCM

or

exosomes of the Neo or M7. The
detection of Tsg101 and Alix were used in combination to verify the isolation of the
exosomes. OF note, different cell lines express different levels of the markers, which is
why the markers were both used. Interestingly, the expression of Tsg101 and Alix are
stronger in the M7 cells than in the Neo cells, yet maspin is not detected in the
exosomes of the M7 cells. The level of maspin in the transfected cells may not be
sufficient to support exosomal maspin. It is possible that cancer cells that still express
endogenous maspin may have lost the ability to efficiently recruit maspin to the
exosomes for detection, which further indicates that exosomal maspin is dysregulated in
the tumor cell.
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Maspin Secretion Occurs by Dual Mechanisms
The two forms of secreted maspin, soluble and exosomal proteins, may be
secreted either dependently, or independently of each other. Various drugs that have
been shown to target specific pathways of secretion were used to help delineate the
secretion mechanism of maspin (Table 4). BFA targets the ER-Golgi trafficking pathway
by inhibiting retrograde transport from the Golgi to the ER.111 IONO is a calcium
ionophore that inhibits ER-Golgi trafficking by disrupting ER calcium levels.112,113 Since
many cellular processes are calcium dependent, ionomycin is may have non-specific
consequences. MA is a weak base that raises the luminal pH of the acidic organelles,
such as the endosome and lysosome.114-116
Table 4: Inhibitors of Secretion
Drug

Targeting Organelle

Brefeldin A (BFA)

ER/Golgi

Ionomycin (IONO)

ER/Golgi

Methylamine (MA)

Endosome

Chloroquine (CQ)

Endosome

The mechanism of methylamine is unclear and may affect other cellular
processes. CQ, an antimalarial drug, is a weak base that raises the luminal pH of acidic
organelles.114,117,118 MA and CQ were used to target endosome trafficking and
subsequently exosome secretion. The CRL2221 cells were treated with or without BFA,
IONO, MA or CQ for 24 h. The lysates, CM, and exosomes were collected and analyzed
with a immunoblot (Figure 10A). Consistent with figure 5, maspin secretion into the
VDCM was not inhibited by BFA. Under BFA treatment, maspin secretion into the
VDCM increased. Moreover, maspin levels in the exosome also increased. In order to
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Figure 10 – Exosomal maspin and soluble maspin are secreted independently. CRL2221
cells were treated with or without 5 µM BFA, 0.1 µM IONO, 1 mM MA or 5 µM CQ for 24
h. (A) Immunoblot analysis of the lysates, VDCM and exosome of the CRL2221 cells. (B)
Zymogram of the CM of the CRL2221 cells. (C) LDH activity assay in the CM of the
CRL2221 cells. Cells treated with BFA and IONO showed significantly different changes in
LDH activity. (*p = <0.001) (D) Cell viability was assessed with the WST-1 reagent. Cells
treated with BFA showed a significant decrease in viability. (*p = <0.001)
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confirm the effect of drug treatment, zymography was used to analyze the CM of the
drug-treated cell (Figure 10B). Zymography of the CM revealed

that the BFA was

effective at inhibiting the ER-Golgi dependent secretion of MMP9. In contrast, targeting
ER-Golgi secretory pathway with ionomycin was less effective and did not inhibit MMP9
secretion. Under IONO treatment, neither the levels of soluble maspin nor exosomal
maspin was affected. MA has been shown to inhibit exosome secretion by some but
was not an effective inhibitor for others.115,116 Under MA treatment, maspin secretion
was not inhibited. On the contrary, maspin secretion slightly increased in the VDCM
and noticeably increased in the exosomes. Under CQ treatment, secretion of soluble
maspin was not affected. However, secretion of exosomal maspin decreased. LDH
activity assay was performed to monitor cell lysis under drug treatment (Figure 10C).
Cell lysis only increased under BFA treatment. Therefore, the presence of maspin in the
VDCM or exosomes was not due to cell lysis. Additionally, WST-1 assay was also
performed in order to monitor cell viability under drug treatment (Figure 10D). BFA
treatment elicited cell stress as judged from the increase in LDH activity and reduced
cell viability. However, BFA was effective at inhibiting classical secretion as judged by
the absence of MMP9 in the CM of BFA treated cells. IONO treatment resulted in a
decrease in LDH activity, which may have been due to the off-target effects of the
calcium ionophore.
It is possible that the soluble maspin may bind to a protein at the surface of the
exosome. It is also possible that maspin is in the lumen of the exosome. To further
investigate the two possibilities, exosomes derived from CRL2221 cells were stripped of
peripheral proteins at the exosome surface with various concentrations of potassium
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chloride (KCl). Low levels of
KCl were used as not to
disrupt

the

exosome

membrane. The levels of
maspin

slightly

decreased

under KCl treatment (Figure
11). However, the exosomal
markers

also

decreased.

Treatment with 25 mM KCl
showed the biggest reduction
Figure 11 – Maspin is not at the membrane surface of
the exosome. Immunoblot analysis of the exosomes
derived from CRL2221 cells after treatment with various
concentrations of KCl. Alix and Tsg101 are markers of the
exosome.

in maspin, Alix and Tsg101.
This may be due to the
treatment conditions since a
new batch of exosomes was

prepared for each condition. The reduction may be due to the loss of exosomes during
the isolation process. The data suggests that maspin is not associated with the surface
of the exosomes but rather the lumen. This is additionally supported by the observation,
from EM, that maspin was easily detected when the lumen of ruptured exosomes was
exposed (Figure 3B). In contrast, maspin was not observed at the surface of the
exosomes visualized by EM. Further confirmation of maspin within the lumen can be
given with experiments such as a protease protection assay.
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Chapter 3B: The biological function of exosomal maspin in paracrine
communication in the microenvironment

Maspin Knockdown in MCF10A Cells
Previous literature on exosomes has shown that the molecular content
associated with the exosome is functional molecules.80,83,95 The Sheng laboratory
showed the impact on tumor expression of maspin on inhibiting stromal reactivity that
may specifically involve endothelial cells.33 To test whether the secreted exosomal
maspin contribute to this tumor suppressive effect, isogenic exosomes with and without
maspin were generated through the knockdown of maspin in the MCF10A
spontaneously immortalized breast cell line, which secretes an abundance of exosomal
maspin. Stable transfected cell lines were generated as described in Materials and
Methods. The level of maspin knockdown in the lysates of the clones was assessed by
immunoblot analysis. The noncoding clones were generated as controls. MCF10A
maspin shRNA clones 3, 7, 8, 9 and 11 showed a reduction in maspin levels in the
lysate (Figure 12A). The levels of maspin in the noncoding clones were comparable to
the parental cell line. Analysis of the VDCM of noncoding clone 1 and 5 revealed
secretion of maspin in clone 1 (NC1) only, which was chosen for application in the
functional assay (Figure 12B). In contrast, secreted maspin was not detected in maspin
shRNA clones 3, 7, 8, and 11. Analysis of the exosomes revealed that exosomal
maspin was detected in the noncoding clone 1 (NC1) but not noncoding clone 5 or
maspin shRNA clones 3, 7, 8, and 11 (Figure 12C). MCF10A maspin shRNA clone 8
(siMas8) was chosen for application in functional assays. The data demonstrate that
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Figure 12 – Knockdown of intracellular maspin affects maspin secretion.
Maspin was knocked down in the MCF10A cells and the levels were determined by
immunoblot analysis of the lysates (A), VDCM (B), and the exosomes (C). The
amount of exosomal maspin was determined by immunoblot analysis. β-tubulin was
used as a loading control. Clone number is indicated above each lane. P = parental
MCF10A cell line
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Figure 13 – Cell viability of the NIH 3T3 cells after exosome treatment. The
NIH 3T3 cells were treated with various concentrations of exosomes for 24 h. The
cell viability was measured with a WST-1 assay.
knockdown of the maspin gene leads to loss of exosomal maspin. The data further
emphasizes that maspin is a bona fide exosomal protein.
In order to investigate the role of exosomal maspin in paracrine communication,
the cell viability of the NIH 3T3 fibroblasts was analyzed (Figure 13). The concentration
of exosomes derived from NC1 and siMas8 were optimized as described in the Material
and Methods. NIH 3T3 mouse fibroblast cells, which do not express maspin, were
treated with various concentrations of the exosomes. After 24 h of treatment, cell
viability of the NIH 3T3 cells was assessed with the WST-1 assay.

Cell viability
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Figure 14 – Exosome uptake by NIH 3T3 fibroblasts. NIH 3T3 cells were treated
with PKH26 labeled exosomes for 24 h and visualized with fluorescence microscopy.
The red fluorescent images were overlaid with phase contrast images of the cells.
decreased as exosome concentration increased (Figure 13). The optimal concentration
of exosomes chosen was at 1:100.
In order for molecular content to exhibit function, the exosomes must be
received by a cell. Next, the uptake of the NC1-derived exosomes and the siMas8derived exosomes were verified. First, the exosomes were labeled with pKH26, a
membrane dye, as described in the Material and Methods section. Then, the NIH 3T3
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cells were treated with PKH26 labeled exosomes isolated from either NC1 or siMas8 at
a 1:100 dilution. Labeling of the exosomes with PKH26 is described in the Material and
Methods. NIH 3T3 cells were incubated with the labeled exosomes for 24 h. NIH 3T3
cells accepted the labeled exosomes as judged by the red fluorescence (Figure 14).
The underlying mechanism of exosome uptake is unknown. As discussed in the
introduciton, there are multiple potential mechanisms for exosome uptake.
The Sheng laboratory has shown that exogenous (rMas) maspin inhibits motility
and invasion of cancer cells.32,41,42 In order to determine the function of exosomal
maspin, I evaluated the effect of exosomal maspin on fibroblast motility. NIH 3T3 cells
were incubated in a 1:100 dilution of exosomes, in DKSFM, that were derived from
either NC1-derived exosomes (NC1 exo) or siMas8-derived exosomes (siMas8 exo) for
24 h. Then, the NIH 3T3 cells were seeded into the upper chamber of transwell plates
and incubated for 24 h. The NIH 3T3 cells that were treated with siMas8-derived
exosomes (maspin negative exosomes) showed a statistically significant increase in
motility compared to the control cells and cells pre-treated with exosomes with maspin
(Figure 15A). Interestingly, motility of NC1 exosome pre-treated cells was comparable
to the control. Representative images of the cells that migrated through the membrane
pores ware shown in Figure 15B. Thus, the loss of maspin seems to stimulate the
motility of the fibroblasts. The data further suggest that the normal epithelial-derived
exosomes may prevent maspin from directly inhibiting fibroblast motility. In order to
determine whether the exosome prevents direct inhibition by maspin, the effect of
soluble maspin on motility is under investigation by the Sheng laboratory. Additionally,
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Figure 15 – Loss of exosomal maspin results in increased motility for NIH 3T3
cells. (A) NIH 3T3 cells were pre-treated with or without exosomes derived from the
noncoding clone or maspin knockdown clones. Motility of the NIH 3T3 cells was
assessed after 24 h. (B) Representative images of the motility of the NIH 3T3 cells
after 24 h.
the Sheng laboratory is also testing a second maspin knockdown clone (siMas11) to
verify that the loss of maspin stimulates NIH 3T3 fibroblast motility.
Based on the evidence that the exosomes were internalized by NIH 3T3 cells
and that maspin is a cargo of the exosome, it is possible that maspin acts inside the
recipient cell once the exosome is internalized. In particular, exosomal maspin may
function in an epigenetic capacity. To test the possibility, qRT-PCR measurements of
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Figure 16 - Messenger RNA levels of various genes in the NIH 3T3 cells after
treatment with exosomes derived from either noncoding clone or maspin
knockdown clones. Qualitative RT-PCR was performed to measure the levels of
mRNA of genes in the NIH 3T3 cells. Analysis of the variance was performed for
statistical data. *p < 0.05 indicates statistical significance.
several HDAC1 target genes (p21, uPA, Col I and vimentin), along with genes
implicated in fibroblast reactivity (Vim and SMA). As shown in figure 16, there was a
statistically significant decrease in collagen 1 in cells pre-treated with NC1 exo (maspin
positive). This suggests that exosomal maspin may specifically suppress the wound
healing activity of the fibroblasts at the step of collagen 1 expression. There was not a
statistical difference in mRNA levels of Col I between NIH 3T3 cells treated with NC1
exo and siMas8 exo. In parallel, although not statistically significant, there was a
trending decrease in p21, an HDAC1 target gene. Thus, internalized maspin may
indeed inhibit HDAC1. Although there was a decrease in uPA in cells treated with NC1
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exo, the change was not statistically significant. Overall, the exosomal maspin seem to
have a limited capacity in causing epigenetic changes. This may be due to the amount
of maspin available via the exosomes.

58
Chapter 4: Discussion
Hypothetical Model
This study suggests that the exosome acts as a barrier between maspin and the
extracellular microenvironment, which gives exosomal maspin a fate that is distinct from
the fate of soluble maspin. Different modes of secretion thereby segregate the functions
of soluble and exosomal maspin. As described in Figure 17, secreted soluble maspin
can interact locally with cell surface proteins, such as its molecular partner, uPA. Cell
surface activity of soluble maspin may be immediate and short-lasting, since soluble
maspin is exposed to the extracellular environment. In contrast, encapsulation of

Figure 17 - Hypothetical Model of the Extracellular Activity of Soluble and
Exosomal Maspin. Soluble maspin acts at the cell surface and has local activity.
The exosomal maspin, because of encapsulation, cannot act the cell surface.
However, exosomal maspin can travel to distant locations to communicate with
target (recipient) cells such as the stromal cells.
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exosomal maspin may serve as a protective barrier from the extracellular environment.
Exosome encapsulation allows maspin to bypass cell surface activity with uPA. Unlike
soluble maspin, the exosomal maspin may have delayed activity because the exosome
has to reach a target cell and be internalized.
The cell can internalize both soluble maspin and exosomal maspin.
Internalization may be the limiting step for exosomal maspin to elicit its function inside
the recipient cell. The actions of soluble maspin may be more immediate after secretion
since it is not encapsulated by the exosome. Once inside of the cell, exosomal maspin
may interact with the same target proteins as internalized soluble maspin. For example,
rMas has been shown to inhibit breast cancer cell motility through inhibition of Rac
signaling and promote cell adhesion through PI3K signaling.44 Therefore, the effect of
maspin on Rac and PI3K signaling is a feasible future direction. Through the exosomes,
maspin is involved in paracrine signaling. It is equally possible that the exosomes can
be involved in autocrine signaling (not depicted in hypothetical model). The exosomes
may also be taken up by neighboring cells and the cell that secreted the exosomes.

Dual and Independent Mechanisms of Secretion of Maspin
This study offers new insights into the secretion of maspin. Since the discovery of
maspin, its secretion has been observed and shown to have tumor suppressive activity.
Additionally, maspin has been reported as an exosomal protein. Maspin was first
demonstrated to be in the exosomes of irradiated H460 lung adenocarcinoma cells.69
The H460 lung adenocarcinoma cells express intracellular maspin but do not secrete
exosomal maspin unless irradiated. This observation is consistent with my data, which
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shows that tumor cells secrete little to no exosomal maspin. Secretion of exosomal
maspin was also shown to differ between undifferentiated and differentiated
keratinocytes.70 Maspin was detected in the exosomes of the undifferentiated
keratinocytes and reported as a 25kDa protein, although the molecular weight of maspin
is 42 kDa. Neither of the previous reports addressed the coexistence of both exosomal
maspin and soluble maspin.
This study is the first to show that exosome-secreted maspin is distinct from the
secreted soluble maspin, since exosomal maspin can be isolated from the conditioned
media (CM), while soluble maspin remains in the CM. The secretion of maspin as either
a soluble or exosomal protein is not mutually exclusive, but concurrent. The
discrimination of exosomal maspin between normal cell lines and tumor cell lines may
indicate maspin secretion via the exosomes is a naturally occurring, regulated process
perturbed in tumor cells. This study suggests that the routes of secretion for soluble
maspin and exosomal maspin are independent and differ mechanistically. Furthermore,
neither soluble maspin nor exosomal maspin depend on the ER-Golgi secretory
pathway.
Exosomal maspin depends on endosome trafficking for secretion. Endosomes
are organelles formed from endocytosis at the plasma membrane.71 After endocytosis,
the endosome undergoes maturation, in which the luminal pH becomes increasingly
acidic as it goes from the early endosome to the late endosome. The endosomes form
intraluminal vesicles (ILVs) to become multivesicular bodies (MVBs). When the
endosome fuses to the plasma membrane, the ILVs are released as exosomes. During
the formation of the ILVs, proteins, such as maspin, are recruited to the endosome
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membrane. The recruitment of proteins may depend on transient ubiquitination of the
protein, followed by de-ubiquitination of the protein after recruitment.77,78 Previously, our
laboratory has shown that maspin was degraded by the proteasome, which is
dependent on ubiquitination.68,119,120 Therefore, it is possible that maspin may be
ubiquitinated and recruited to the endosome membrane during ILV formation. Inhibition
of endosome trafficking with chloroquine (CQ), an anti-malarial drug that increases the
pH of the endosome, subsequently inhibits exosome secretion and exosomal maspin
levels. However, it is unclear at which point of the endosome trafficking process
(endosome plasma membrane fusion, ILV formation, exosome secretion, etc.) is
targeted by CQ to affect exosomal maspin secretion.
This study demonstrates that inhibiting the secretion of exosomal maspin does
not affect the secretion of soluble maspin. Currently, the mechanism of secretion of
soluble maspin is not clear. Efforts to ascertain the mechanism revealed that drugs
commonly used to inhibit various secretion pathways did not inhibit the secretion of
soluble maspin. In contrast, secretion of soluble maspin increased under drug
treatment, as well as general cellular stress. Fusion of the endosome to the plasma
membrane may release exosomes, as well as soluble proteins. Soluble maspin is most
likely not secreted by the endosomes since drugs targeting endosome trafficking did not
inhibit soluble maspin, but by an alternative non-classical pathway. Non-classical
secretion may occur by different mechanisms, which may be vesicular or non-vesicular.
Microvesicles, such as exosomes, membrane blebs, and apoptotic bodies, represent
vesicular methods of secretion. There are also several non-vesicular routes of non-
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classical secretion, such as direct translocation across the plasma membrane. Further
investigation into the mechanism of secretion of soluble maspin is warranted.

Exosomal Maspin and Tumor Progression
This study is the first to demonstrate that fibroblast motility is stimulated by
exosomes that have loss maspin. Interestingly, although maspin has been shown to
inhibit cell motility, treatment with NC1 exo, which contain maspin, did not inhibit the
motility of the NIH 3T3 cells. Our data raised the possibility that normal cell-derived
exosomes may be naïve but may become tumor promoting when maspin is down
regulated. The loss of exosomal maspin may result in early gain of function for stromal
cells in the tumor microenvironment. Alternatively, exosomal maspin may be sufficient
to block the activation or activity of mesenchymal cells, which is lost when maspin is
down regulated. It was previously reported that extracellular maspin readily inhibits
tumor cell motility and invasion in vitro.121 While further studies are underway to dissect
the differences between soluble maspin and exosomal maspin, internalization of
exosomal maspin may have tumor-suppressive activity.
At the molecular level, the Sheng laboratory identified maspin as the first
polypeptide inhibitor of HDAC1 thus far.49,50 Data from this study suggests that
exosomal maspin may exert its biological effects without significantly altering the
expression of many HDAC1 target genes. In order to validate our observations, a wider
array of HDAC1 target genes needs to be tested. It was noted that the presence of
exosomal maspin resulted in a decrease in collagen I mRNA in NIH 3T3 cells, while the
absence of exosomal maspin resulted in an increase in NIH 3T3 cell motility. Thus, the
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underlying mechanism for the effect of maspin on mesenchymal cells may differ from
that on epithelial cells. The data are the first to show that the biological functions of
exosomal maspin may be differentially regulated in the continuum of tumor progression.
Proteins undergo aberrant trafficking in tumor cells as a response to
transformation and the challenges of tumor microenvironment. The secretion of maspin
may be subjected to differential regulation by tumor cells in response to epithelial
transformation and changes within the tumor microenvironment. The data show that
soluble maspin is secreted at a lower level in maspin-expressing tumor cell lines than
normal cell lines. In comparison, exosomal maspin was barely detectable in tumor cell
lines that express various levels of intracellular maspin. This is the first evidence that
exosomes produced by normal and tumor cells have distinct features. This data is
consistent with Yu et. al. (2006) who showed that exosomes derived from H460 lung
adenocarcinoma cells did not express maspin when cells were grown under exponential
growth conditions. In contrast, maspin expression was induced in the exosomes through
irradiation of the H460 cells. While the loss of secreted soluble maspin may be coupled
with the down-regulation of intracellular maspin, the loss of exosomal maspin may occur
before the down-regulation of intracellular maspin. This may be due to early
dysregulation of exosome machinery in tumorigenesis, since the molecular content of
the normal cell-derived and tumor cell-derived exosomes differ. During biogenesis of the
exosomes as ILVs, cytoplasmic proteins are recruited to the invaginated endosome
membrane. Cytoplasmic maspin levels increase during tumor progression at the stage
of pre-neoplastic lesions.29,52 Therefore, we speculate that an increase in cytoplasmic
maspin may increase the amount of maspin recruited to the endosome. This study is
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the first to show that exosomal maspin may also be down regulated during tumor
progression. Further investigation is needed to determine whether biphasic expression
of intracellular maspin affects exosomal maspin.
Equally possible, an increase in cytoplasmic maspin may not affect the amount of
maspin recruited to the endosome. The ESCRT proteins are responsible for the
recruitment of proteins, as well as ILV formation, scission, and back-fusion.77,78 In line
with the function of the ESCRT proteins, recruitment of maspin most likely depends on a
particular set of ESCRT proteins. Loss of exosomal maspin may occur if those ESCRT
proteins are down regulated in tumor. Further investigation is necessary to determine
whether loss of maspin in tumor cell-derived exosomes occurs at the recruitment stage
of ILV formation.
The data reported here are the first evidence that the exosomes derived from
normal cells have a distinct size distribution pattern from the exosomes derived from
tumor cells. Dynamic light scattering revealed two distinct populations of particles
enriched from the normal-derived exosome fraction by differential centrifugation. The
first population is below 100 nm in diameter, with an average size consistent with
exosome size range, which suggests the first population is the exosomes. In contrast,
the second population was absent in the exosome fraction isolated from tumor cells.
Therefore, the second population is a novel population of particulates secreted by the
normal cells. Despite the presence of the second population, the zeta potential of both
normal- and tumor-derived exosome fractions was negative. Given these observations,
further investigation is necessary to evaluate the significance of the second population
detected in the normal-derived exosome fraction.
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The quality of our subcellular fractionation and exosomal purification was
ascertained by multiple approaches. My experiments were performed under exponential
cell growth condition, without detectable cell lysis or cell death. The tumor cell-derived
exosomes lost maspin, which was disproportional to the overall changes of maspin
expression. Considering the earlier report that maspin was detected in exosomes of
H460 lung adenocarcinoma cells only when the cells were irradiated, it seems
necessary to caution that irradiation may damage the integrity of cellular structure and
lead to contamination of the exosomal fraction with other microvesicles and lytic cell
debris.69

Diagnostic Potential of Exosomal Maspin
Combined with the previous literature showing that exosomes circulate in bodily
fluids, my novel observations indicate that exosomal maspin status may be a potential
diagnostic marker. Our study is the first to demonstrate that maspin is consistently
expressed in exosomes produced by normal cell lines, but not in tumor-derived
exosomes. This expression pattern of exosomal maspin is distinct from the expression
patterns of soluble maspin and intracellular maspin. Exosomal maspin may be lost
before intracellular maspin is lost. The loss of exosomal maspin may pinpoint an early
stage in tumor progression, which would advantageous for the early detection of
aberrant cells. As a diagnostic marker, the status of maspin in the exosome could
indicate whether or not a patient has aberrant cells present in the body. More
specifically, the lack of maspin in the exosomes may indicate the presence of aberrant
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cells. The presence of maspin in the exosomes may indicate a normal state of the cells
in the body.
In order to establish exosomal maspin as a diagnostic tool, a major limitation
would have to be addressed. The limitation is that bodily fluids contain a mixture of
exosomes derived from various cellular origins. Although the exosomes can be isolated
from the bodily fluids, the presence of many different exosomes may dilute the amount
of exosomal maspin. The limitation can be addressed by creating diagnostic tools that
are specific and sensitive to epithelial exosomes and exosomal maspin. Maspin is
expressed solely in epithelial cells and, as a result, epithelial-derived exosomes.
Therefore, an assay may be developed to isolate epithelial-derived exosomes with an
antibody targeting an exosomal transmembrane protein of epithelial origin. Then, the
epithelial-derived exosomes may be analyzed for exosomal maspin and compared to a
baseline level of exosomal maspin. Since many solid tumors are of epithelial origin, the
epithelial-derived exosomes may be a mixture of normal cell-derived exosomes and
tumor-derived exosomes. In conjunction with isolating the epithelial-derived exosomes,
the tumor-derived exosomes may be further isolated from the normal-derived exosomes
with an antibody specific to a transmembrane protein tumor-derived exosomes. Then,
the status of exosomal maspin may be determined. Of note, the exosome field is
investigating the molecular content of tumor-derived exosomes in order to establish
reliable, specific tumor-derived exosome markers. Further investigation is needed to
determine whether maspin’s status in the exosome may be a beneficial diagnostic
marker.
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The diagnostic potential of the exosomes is of interest because the exosomes
may provide a non-invasive method for cancer diagnosis. The feasibility of using
exosomes as diagnostic markers is already being explored in the science industry. For
example, Exosome Diagnostics, Inc. and Exosome Sciences, Inc. are two companies
that are developing assays to use exosomes as diagnostic tools. These companies
have a particular interest in exosomal miRNA for diagnostics and therapeutics. My
research suggests that exosomal maspin may provide a basis for a novel protein-based
diagnostic tool.

Prognostic Potential of Exosomal Maspin
Correlation of intracellular maspin expression to patient outcome differs across
various cancer types differs. Additionally, not all cancer cells lose intracellular maspin
expression. Of note, strong nuclear expression of maspin was shown to correlate with
increased overall patient survival in comparison to strong cytoplasmic expression and
loss of intracellular maspin.52,54,55 However, there are limitations in determining clinical
outcome based on nuclear maspin expression. Our data indicates maspin positive
aberrant cells of various origins lose exosomal maspin. In addition, my data show that
forced re-expression of maspin in maspin negative tumor cells does not automatically
reinstate exosomal maspin. Yu et al (2006) showed that subjecting cancer cells to
radiation induced the presence of exosomal maspin. Our data indicate that exosomal
maspin may have tumor suppressive activity. However, we do not know whether
induction of exosomal maspin in tumor cells would correlate with a better clinical
outcome. The prognostic value of exosomal maspin may rely on establishing a

68
correlation between induced exosomal maspin after therapeutic drug treatment and
better overall survival. If induction of exosomal maspin correlates to a positive
therapeutic drug response, then exosomal maspin would serve as a novel prognostic
marker. Further investigation is necessary to determine the prognostic value of
exosomal maspin after therapeutic drug treatment.

Therapeutic Potential of Exosomal Maspin
The tumor-suppressive activity of maspin makes it a protein of therapeutic
interest. Re-expression of maspin in tumor cell lines resulted in sensitivity to druginduced apoptosis. In our model, we showed that re-expression of maspin was not
sufficient to restore exosomal maspin. The exosomes represent a natural mechanism
for delivering molecular materials. Currently, synthetic liposomes are being developed
as drug delivery systems. Maspin may have therapeutic use as a tumor suppressor by
packing maspin into synthetic liposomes. Combined with data that exosomal maspin
has tumor suppressive activity, delivery of maspin via synthetic liposomes may be
beneficial for anti-tumor response.
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This dissertation highlights several novel findings. Maspin has been consistently
detected in the conditioned media of maspin-expressing cells of normal and tumor
breast, prostate and lung origin. Furthermore, extracellular maspin has been
demonstrated to have anti-tumor effects. Interestingly, maspin has been reported as
cargo of the exosomes, which highlights one of the secretion mechanisms of maspin.
Maspin secretion as an exosomal molecule was verified by electron microscopy, atomic
force microscopy, light scattering dynamic analysis and immunoblot analysis.
The data showed that exosomes derived from the non-malignant cell lines have
two distinct populations that do no overlap in their size distributions. Based on the size
distribution and the electron microscopy analysis, it is likely that exosomes derived from
the non-malignant cells are aggregated exosomes.. In contrast, tumor cell-derived
exosomes comprised a population of broader size distribution.
To understand how secreted maspin may contribute to tumor suppression, it is
critical to understand how maspin is regulated at the step of protein trafficking. The data
showed that maspin is secreted by dual mechanisms, as free and exosomal protein,
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respectively. These two mechanisms seem to be independent. While tumor cells are
capable of secreting maspin as a free molecule, albeit at a lower level as compared to
that by normal epithelial cells, they do not secrete exosomal maspin.
Loss of maspin in exosomes from derived non-malignant cells conferred a
stimulatory effect on the motility of fibroblasts, suggesting a biological function of
exosomal maspin in suppressing the stromal reactivity in the tumor microenvironment.
These novel findings highlight a new role for exosomal maspin as a tumor suppressor.
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